AN OPEN-LABEL STUDY OF GV20-0251 IN PATIENTS WITH ADVANCED AND/OR REFRACTORY SOLID TUMOR MALIGNANCIES

Brief description of study

This study has two parts, Part A and Part B, and will be testing the drug GV20-0251 to see how well it can help patients with advanced or refractory solid tumor malignancies. In Part A, the study will test the drug GV20-0251 to find the highest dose that can be bearable by patients without severe side effects. The dosages will gradually increase for patients and the patients will be closely monitored during this phase. In Part B, eligible partients will receive the recommended dose of GV20-0251 determined to be safe for patients in Part A. The study team will study the drug's safety, how the body processes it, its effects on the patients, and its impact on tumors in specific types of cancer. Patients will be evaluated, undergo treatment cycles, and have follow-up visits to assess their well-being. The study will be considered complete when all patients have finished treatment and the required follow-up visits.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.